



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 113405

To: Sean McGarry
Location: rem/2d19/2c18
Art Unit: 1635
Thursday, February 05, 2004

Case Serial Number: 09/744875

From: Beverly Shears
Location: Remsen Bldg.
RM 1A54
Phone: 571-272-2528
beverly.shears@uspto.gov

Search Notes

SEARCH REQUEST FORM

Requestor's Name: _____ Serial Number: _____
Date: _____ Phone: _____ Art Unit: _____

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

STAFF USE ONLY

Date completed: 02-05-04
Searcher: Bacry C 2525
Terminal time: 24
Elapsed time: _____
CPU time: _____
Total time: 29
Number of Searches: _____
Number of Databases: 2

Search Site
____ STIC
____ CM-1
____ Pre-S
Type of Search
____ N.A. Sequence
____ A.A. Sequence
____ Structure
____ Bibliographic

Vendors
____ IG
☒ STN
____ Dialog
____ APS
____ Geninfo
____ SDC
____ DARC/Questel
☒ Other CGN

McGarry
091744875

09/744875

FILE 'REGISTRY' ENTERED AT 15:11:46 ON 05 FEB 2004

L1 116 SEA FILE=REGISTRY ABB=ON PLU=ON AGATTTCTAGGAATTCAAATC|G
CCTGATTTCCCCGAAATGACGGCA|GTATTTCCCAGAAAAGGAAC/SQSN
L2 37 SEA FILE=REGISTRY ABB=ON PLU=ON L1 AND SQL=<100

FILE 'HCAPLUS' ENTERED AT 15:13:55 ON 05 FEB 2004

L3 16 S L2

09/744875

FILE 'REGISTRY' ENTERED AT 15:11:46 ON 05 FEB 2004

L1 116 S AGATTCTAGGAATTCAAATC | GCCTGATTTCCTCCGAAATGACGGCA | GTA
L2 37 S L1 AND SQL=<100

FILE 'HCAPLUS' ENTERED AT 15:13:55 ON 05 FEB 2004

L3 16 S L2

L3 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:571117 HCAPLUS

DOCUMENT NUMBER: 139:132464

TITLE: Cytokine zcytor17 ligand, polynucleotides and antibodies for diagnosis and treatment of acute inflammatory diseases

INVENTOR(S): Sprecher, Cindy A.; Kuijper, Joseph L.; Dasovich, Maria M.; Grant, Francis J.; Hammond, Angela K.; Novak, Julia E.; Gross, Jane A.; Dillon, Stacey R.

PATENT ASSIGNEE(S): Zymogenetics, Inc., USA

SOURCE: PCT Int. Appl., 372 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003060090	A2	20030724	WO 2003-US1984	20030121
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2003224487 A1 20031204 US 2003-352554 20030121

PRIORITY APPLN. INFO.: US 2002-350325P P 20020118

US 2002-375323P P 20020425

US 2002-435315P P 20021219

AB The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody mols. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells or hematopoietic cell progenitors in vitro and in vivo. The present invention also includes methods for producing the protein, polynucleotides and antibodies for diagnosis and treatment of acute inflammatory diseases such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, atopic dermatitis, eczema, psoriasis, endotoxemia, septicemia, toxic shock syndrome, and infectious disease.

IT 566963-54-0, 43: PN: WO03060090 SEQID: 44 claimed DNA

RL: ARU (Analytical role, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

09/744875

(cytokine zcytor17 ligand for hematopoietic cell expansion and
for diagnosis and treatment of acute inflammatory diseases)

L3 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:377006 HCAPLUS
DOCUMENT NUMBER: 138:380415
TITLE: Protein and cDNA sequences of mutant
interleukin-21 proteins and use as IL-21
antagonists
INVENTOR(S): Presnell, Scott R.; West, James W.; Novak, Julia
E.
PATENT ASSIGNEE(S): Zymogenetics, Inc., USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040313	A2	20030515	WO 2002-US34502	20021028
WO 2003040313	A3	20030925		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

US 2003134390 A1 20030717 US 2002-282622 20021028

PRIORITY APPLN. INFO.: US 2001-337586P P 20011105

AB The invention provides protein and cDNA sequences of two
interleukin-21 mutants that are IL-21 antagonists that bind with
specificity and exhibit an EC50 that is not detectable in receptor
binding studies. These mols. have mutations in the D helix of the
IL-21 mol., and can be used to inhibit the activity of IL-21 with
its cognate receptor.

IT 524984-78-9

RL: PRP (Properties)

(unclaimed nucleotide sequence; protein and cDNA sequences of
mutant interleukin-21 proteins and use as IL-21 antagonists)

L3 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:58698 HCAPLUS
DOCUMENT NUMBER: 138:119583
TITLE: Method for detecting transcription
factor-protein interactions
INVENTOR(S): Li, Xianqiang
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of
U.S. Ser. No. 877,738.
CODEN: USXXCO
DOCUMENT TYPE: Patent

Searcher : Shears 571-272-2528

09/744875

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003017499	A1	20030123	US 2001-947274	20010905
US 2003008283	A1	20030109	US 2001-877705	20010608
US 2003022173	A1	20030130	US 2001-877738	20010608
WO 2002101351	A2	20021219	WO 2002-US17408	20020530
WO 2002101351	A3	20030626		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2001-877243 A2 20010608
US 2001-877403 A2 20010608
US 2001-877705 A2 20010608
US 2001-877738 A2 20010608
US 2001-947274 A1 20010905

AB A method is provided for identifying complexes between a transcription factor and another protein, the method comprising: isolating from a biol. sample transcription factor complexes based on whether the transcription factor complexes comprise a particular type of transcription factor; and identifying which of a plurality of different proteins are present in the isolated transcription factor complexes. A library of transcription factor DNA probes was contacted with nuclear exts. of untreated and PMA-treated A431 cells and then with arrays of transcription factor hybridization probes. By comparing images for each, transcription factors NF-E1 and NF- κ B were found to be activated by PMA in A431 cells.

IT 488765-15-7D, biotin-labeled
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(nucleotide sequence, transcription factor probe; detection of transcription factor-protein interactions)

L3 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:964602 HCAPLUS
DOCUMENT NUMBER: 138:34116
TITLE: Capture of activated transcription factors by specific DNA binding and analysis of the protein composition of the complex
INVENTOR(S): Li, Xianqiang
PATENT ASSIGNEE(S): Panomics, Inc., USA
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

Searcher : Shears 571-272-2528

09/744875

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
2002101351	A2	20021219	WO 2002-US17408	20020530
2002101351	A3	20030626		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003008283	A1	20030109	US 2001-877705	20010608
US 2003022173	A1	20030130	US 2001-877738	20010608
US 2003017499	A1	20030123	US 2001-947274	20010905
PRIORITY APPLN. INFO.:			US 2001-877243	A1 20010608
			US 2001-877403	A1 20010608
			US 2001-877705	A1 20010608
			US 2001-877738	A1 20010608
			US 2001-947274	A1 20010905
AB	A method of identifying proteins bound to a transcription factor in an activate transcription factor complex is described. The transcription factor is captured from a cell or nuclear extract using a capture probe containing a specific transcription factor binding site. The complexes are recovered by agarose gel electrophoresis under conditions that do not disrupt the complex and the proteins then analyzed. The method can be used to analyze nos. of transcription factor complexes in parallel and in several different tissues, e.g. comparing transcription factors in normal and neoplastic cells.			
IT	478608-20-7 RL: PRP (Properties) (unclaimed nucleotide sequence; capture of activated transcription factors by specific DNA binding and anal. of the protein composition of the complex)			
L3	ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN			
ACCESSION NUMBER:	2002:946321 HCAPLUS			
DOCUMENT NUMBER:	138:34237			
TITLE:	Transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent			
INVENTOR(S):	Tovey, Michael			
PATENT ASSIGNEE(S):	Centre National de la Recherche Scientifique, Fr.			
SOURCE:	PCT Int. Appl., 84 pp. CODEN: PIXXD2			
DOCUMENT TYPE:	Patent			
LANGUAGE:	English			
FAMILY ACC. NUM. COUNT:	1			
PATENT INFORMATION:				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Searcher : Shears 571-272-2528

09/744875

WO 2002098916 A2 20021212 WO 2002-EP7064 20020606
WO 2002098916 A3 20031106

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.: EP 2001-401476 A 20010607

OTHER SOURCE(S): MARPAT 138:34237

AB Constitutive expression of the tumor suppressor genes p53 and IRF1 (interferon regulatory factor 1) is required for the maintenance of the cellular growth control during genotoxic damage or aberrant proliferation. A transcriptional regulatory element within the promoter region of both the p53 and IRF-1 genes which binds a pos. transcription factor, denoted GAAP-1 or GAAP-2 (IRF1 p53 common sequence binding factor). The invention relates to the identification and cloning of the GAAP-1 or GAAP-2 cDNA and to the identification of the encoded protein corresponding to the 75kDa product of the alternatively sliced PRDII-BF1 mRNA precursor.

IT 478232-52-9

RL: PRP (Properties)

(unclaimed sequence; transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent)

L3 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:466705 HCAPLUS

DOCUMENT NUMBER: 137:52346

TITLE: Methods of treating colitis using STAT-4 anti-sense oligonucleotides

INVENTOR(S): Strober, Warren; Fuss, Ivan; Neurath, Markus; Kitani, Atsushi

PATENT ASSIGNEE(S): The Government of the United States of America, Department of Health and Human Services, USA

SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont. of U.S. Ser. No. 535,025, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002077308	A1	20020620	US 2001-812028	20010319
US 6479465	B2	20021112		

PRIORITY APPLN. INFO.:

US 1999-125877P P 19990324

US 2000-535025 B1 20000324

AB The present invention provides a method of treating or preventing the inflammatory response of an inflammatory bowel disease in a subject, comprising administering to the subject an amount of a STAT-4 antisense oligonucleotide effective in treating or preventing the

09/744875

inflammatory response of the inflammatory bowel disease.

IT 438069-80-8

RL: PRP (Properties)

(unclaimed nucleotide sequence; methods of treating colitis using
STAT-4 anti-sense oligonucleotides)

L3 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:220778 HCAPLUS

DOCUMENT NUMBER: 136:261808

TITLE: New Toll-like receptors of mouse and their use
in high throughput screening for CpG methylated
DNA for use as immunomodulator

INVENTOR(S): Bauer, Stefan; Lipford, Grayson; Wagner, Hermann

PATENT ASSIGNEE(S): Coley Pharmaceutical G.m.b.H., Germany

SOURCE: PCT Int. Appl., 194 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022809	A2	20020321	WO 2001-US29229	20010917
WO 2002022809	C2	20030320		
WO 2002022809	A3	20031002		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

AU 2001091096 A5 20020326 AU 2001-91096 20010917

US 2003104523 A1 20030605 US 2001-954987 20010917

EP 1366077 A2 20031203 EP 2001-971181 20010917

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2000-233035P P 20000915

US 2001-263657P P 20010123

US 2001-291726P P 20010517

US 2001-300210P P 20010622

WO 2001-US29229 W 20010917

AB The invention pertains to murine TLR9 (Toll-like receptor 9) and related Toll-like receptors and DNAs encoding them. The present invention also includes fragments and biol. functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 mols. which include murine-specific amino

09/744875

acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biol. functional variants of the murine TLR7 and TLR8. Methods are included for screening for ligands of TLR7 and TLR8, as well as for inhibitors and agonists and antagonists of signaling mediated by TLR7 and TLR8. Use of the mouse TLR-9 receptor to drive NF- κ B-dependent expression of a luciferase reporter gene in 293 cells is demonstrated.

IT 405193-24-0

RL: PRP (Properties)

(unclaimed nucleotide sequence; new Toll-like receptors of mouse and their use in high throughput screening for CpG methylated DNA for use as immunomodulator)

L3 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:10536 HCAPLUS

DOCUMENT NUMBER: 136:84703

TITLE: Cytokine receptor zcytor17

INVENTOR(S): Sprecher, Cindy A.; Presnell, Scott R.; Gao, Zeren; Whitmore, Theodore E.; Kuijper, Joseph L.; Maurer, Mark F.

PATENT ASSIGNEE(S): Zymogenetics, Inc., USA

SOURCE: PCT Int. Appl., 235 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000721	A2	20020103	WO 2001-US20484	20010626
WO 2002000721	A3	20030417		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2003096339	A1	20030522	US 2001-892949	20010626
EP 1325115	A2	20030709	EP 2001-952259	20010626
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004501628	T2	20040122	JP 2002-505843	20010626
PRIORITY APPLN. INFO.:			US 2000-214282P	P 20000626
			US 2000-214955P	P 20000629
			US 2001-267963P	P 20010208
			WO 2001-US20484	W 20010626

AB Novel polypeptides, polynucleotides encoding the polypeptides, and related compns. and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro

09/744875

and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

IT 387408-25-5

RL: PRP (Properties)

(unclaimed nucleotide sequence; cytokine receptor zcytor17)

L3 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:763059 HCAPLUS

DOCUMENT NUMBER: 135:317481

TITLE: Soluble zalphall cytokine receptors

INVENTOR(S): Sprecher, Cindy A.; Novak, Julia E.; West, James

W.; Presnell, Scott R.; Holly, Richard D.;

Nelson, Andrew J.

PATENT ASSIGNEE(S): ZymoGenetics, Inc., USA

SOURCE: PCT Int. Appl., 243 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077171	A2	20011018	WO 2001-US10872	20010403
WO 2001077171	A3	20020516		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002137677	A1	20020926	US 2001-825561	20010403
EP 1303602	A2	20030423	EP 2001-926604	20010403
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.:

US 2000-194731P P 20000405

US 2000-222121P P 20000728

WO 2001-US10872 W 20010403

AB The authors disclose the preparation, structural characterization, and ligand antagonist activity of soluble homodimeric and heterodimeric receptors for zalphall. In addition, the construction of epitope-tagged and chimeric receptors and immunoadhesins are described.

IT 309905-34-8, GenBank AX047032

RL: PRP (Properties)

(unclaimed nucleotide sequence; soluble zalphall cytokine receptors)

L3 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:814621 HCAPLUS

Searcher : Shears 571-272-2528

09/744875

DOCUMENT NUMBER: 133:359539
 TITLE: Mouse cytokine receptor zcytor10 and cDNA
 INVENTOR(S): Presnell, Scott R.; Foster, Donald C.; Hammond, Angela K.; Lok, Si
 PATENT ASSIGNEE(S): Zymogenetics, Inc., USA
 SOURCE: PCT Int. Appl., 134 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000068381	A1	20001116	WO 2000-US12924	20000511
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1185641 A1 20020313 EP 2000-928962 20000511 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO JP 2002543786 T2 20021224 JP 2000-616347 20000511 US 1999-309861 A 19990511 WO 2000-US12924 W 20000511				
PRIORITY APPLN. INFO.: AB Novel polypeptides, polynucleotides encoding the polypeptides, and related compns. and methods are disclosed for mouse zcytor10, a novel mouse cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells. Ligand-binding receptor polypeptides can also be used to block ligand activity. The polynucleotides encoding mouse zcytor10 can be used to identify a human ortholog. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. A partial cDNA for the rat homolog of mouse zcytor10 was also cloned and sequenced.				
IT 309905-34-8, GenBank AX047032 RL: PRP (Properties) (unclaimed nucleotide sequence; mouse cytokine receptor zcytor10 and cDNA)				
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

AB Novel polypeptides, polynucleotides encoding the polypeptides, and related compns. and methods are disclosed for mouse zcytor10, a novel mouse cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells. Ligand-binding receptor polypeptides can also be used to block ligand activity. The polynucleotides encoding mouse zcytor10 can be used to identify a human ortholog. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. A partial cDNA for the rat homolog of mouse zcytor10 was also cloned and sequenced.

IT 309905-34-8, GenBank AX047032
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; mouse cytokine receptor zcytor10 and cDNA)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:646143 HCAPLUS
 DOCUMENT NUMBER: 133:248680
 TITLE: Novel human cytokine zalphall1 ligand with therapeutic applications for eye disease
 INVENTOR(S): Novak, Julia E.; Presnell, Scott R.; Sprecher, Cindy A.; Foster, Donald C.; Holly, Richard D.; Gross, Jane A.; Johnston, Janet V.; Nelson, Andrew J.; Dillon, Stacey R.; Hammond, Angela K.

09/744875

PATENT ASSIGNEE(S): Zymogenetics, Inc., USA
SOURCE: PCT Int. Appl., 256 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000053761	A2	20000914	WO 2000-US6067	20000309
WO 2000053761	A3	20001221		
W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
US 6307024	B1	20011023	US 2000-522217	20000309
EP 1165791	A2	20020102	EP 2000-916164	20000309
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		
BR 2000008772	A	20020507	BR 2000-8772	20000309
JP 2002537839	T2	20021112	JP 2000-603382	20000309
US 2002128446	A1	20020912	US 2001-923246	20010803
US 6605272	B2	20030812		
NO 2001004364	A	20011109	NO 2001-4364	20010907
US 2003125524	A1	20030703	US 2002-295723	20021115
US 6686178	B2	20040203		

PRIORITY APPLN. INFO.:

US 1999-264908	A	19990309
US 1999-265992	A	19990311
US 1999-142013P	P	19990701
US 1999-123547P	P	19990309
US 1999-123904P	P	19990311
US 2000-522217	A3	20000309
WO 2000-US6067	W	20000309

AB The present invention relates to zalphall Ligand polynucleotide and polypeptide mols. The zalphall Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo . The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

IT 294679-80-4

RL: PRP (Properties)

(unclaimed nucleotide sequence; novel human cytokine zalphall ligand with therapeutic applications for eye disease)

L3 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:98716 HCAPLUS

DOCUMENT NUMBER: 132:146659

TITLE: Method using oligonucleotides for the modulation of function of transcription factors, and therapeutic use

INVENTOR(S): Zuckerman, Kenneth S.; Liu, Richard Y.

PATENT ASSIGNEE(S): University of South Florida, USA

09/744875

SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006696	A2	20000210	WO 1999-US17366	19990730
WO 2000006696	A3	20000316		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9953295	A1	20000221	AU 1999-53295	19990730
------------	----	----------	---------------	----------

PRIORITY APPLN. INFO.: US 1998-94695P P 19980730
WO 1999-US17366 W 19990730

AB A method is provided for modulating the function of a transcription factor by administering an effective amount of an oligonucleotide containing optimal nucleotide binding sites for the transcription factor. A therapeutic agent having an effective amount of an oligonucleotide for modulating function of transcription factors and a pharmaceutically acceptable carrier is also provided. Also provided is a treatment of patients having illnesses in which the activation of transcription factors play a role by administering to a patient an effective amount of an oligonucleotide which competitively binds the related transcription factor.

IT 175280-54-3 257898-64-9 257898-65-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligonucleotides for modulation of transcription factor function, and therapeutic use)

L3 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:501153 HCAPLUS

DOCUMENT NUMBER: 129:166205

TITLE: Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination

INVENTOR(S): Lipford, Grayson B.; Wagner, Hermann; Heeg, Klaus

PATENT ASSIGNEE(S): Germany

SOURCE: Eur. Pat. Appl., 28 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

09/744875

EP 855184 A1 19980729 EP 1997-101019 19970123
R: DE
WO 9832462 A1 19980730 WO 1998-EP367 19980123
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9862934 A1 19980818 AU 1998-62934 19980123
AU 724325 B2 20000914
EP 971736 A1 20000119 EP 1998-906886 19980123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
PT, IE, SI, LT, LV, FI, RO
JP 2001508780 T2 20010703 JP 1998-531592 19980123
PRIORITY APPLN. INFO.: EP 1997-101019 A 19970123
WO 1998-EP367 W 19980123
AB The invention discloses a pharmaceutical composition comprising at least
one fragment of a polynucleotide and at least one antigen, especially for
the preparation of a vaccine.
IT **211046-24-1**
RL: PEP (Physical, engineering or chemical process); PRP
(Properties); THU (Therapeutic use); BIOL (Biological study); PROC
(Process); USES (Uses)
(pharmaceutical composition comprising a polynucleotide and an antigen
especially for vaccination)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN
THE RE FORMAT
L3 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:49290 HCAPLUS
DOCUMENT NUMBER: 126:166477
TITLE: Peptides derived from the IL-4 Stat
transcription factor and IL-4 receptor for use
as immunomodulators
INVENTOR(S): McKnight, Steven L.; Hou, Jinzhao
PATENT ASSIGNEE(S): Tularik, Inc., USA
SOURCE: U.S., 32 pp., Cont.-in-part of U.S. Ser. No.
269,604, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5591825	A	19970107	US 1994-276099	19940715
AU 9523383	A1	19960118	AU 1995-23383	19950703
AU 679370	B2	19970626		
CA 2153180	AA	19960106	CA 1995-2153180	19950704
CA 2153180	C	20010403		
EP 692488	A2	19960117	EP 1995-304715	19950705
EP 692488	A3	19990317		

09/744875

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL,
PT, SE

JP 08067699 A2 19960312 JP 1995-169439 19950705
JP 2793977 B2 19980903
US 5710266 A 19980120 US 1997-781890 19970105

PRIORITY APPLN. INFO.: US 1994-269604 B2 19940705
US 1994-276099 A 19940715

AB Methods for identifying peptides derived from the transcription factor IL-4 Stat (signal transduction and activator of transcription) and the interleukin 4 receptor and the peptides themselves are described for use in the diagnosis and treatment of disease associated with abnormalities of interleukin 4 function. Genes encoding biol. active peptides derived from these proteins may be used in peptide manufacture or in gene therapy. Similarly, antibodies to the proteins may also be of therapeutic use. The disclosed pharmaceutical screening methods are particularly suited to high-throughput screening where one or more steps are performed by a computer controlled electromech. robot comprising an axial rotatable arm. The ability of phosphotyrosine peptides derived from the IL4 receptor to inhibit the binding of IL-4 Stat to IL4 Stat-binding sites of DNA in vitro is demonstrated.

IT 175280-54-3

RL: BPR (Biological process); BSU (Biological study, unclassified);
PRP (Properties); BIOL (Biological study); PROC (Process)
(inhibition of IL4 Stat binding to; peptides derived from IL-4
Stat transcription factor and IL-4 receptor for use as
immunomodulators)

L3 ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:214782 HCAPLUS

DOCUMENT NUMBER: 124:281083

TITLE: Identifying agents that bind the interleukin 4
signal transducer and transcription activator
for potential therapeutic use

INVENTOR(S): Mcknight, Steven L.; Hou, Jinzhao

PATENT ASSIGNEE(S): Tularik, Inc., USA

SOURCE: Eur. Pat. Appl., 22 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 692488	A2	19960117	EP 1995-304715	19950705
EP 692488	A3	19990317		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL,
PT, SE

US 5591825 A 19970107 US 1994-276099 19940715

PRIORITY APPLN. INFO.: US 1994-269604 A 19940705
US 1994-276099 A 19940715

AB Methods and compns. for identifying pharmacol. agents useful in the diagnosis or treatment of disease associated with the expression of a gene modulated by an interleukin 4 signal transducer and activator of transcription, IL-4 Stat, are described. IL-4 Stat peptides and IL-4 receptor peptides and nucleic acids encoding such peptides find therapeutic uses. The peptides may inhibit IL-4 Stat binding to the

receptor or to their DNA binding site. The subject comps. include IL-4 Stat and IL-4 receptor proteins, portions thereof, nucleic acids encoding them, and specific antibodies. The disclosed pharmaceutical screening methods are particularly suited to high-throughput screening where one or more steps are performed by a computer controlled electromech. robot comprising an axial rotatable arm. Purification of IL-4 Stat and demonstration of inhibition by IL-4 receptor peptides is demonstrated. Receptor peptides that bind IL-4 Stat prevent formation of the active dimer form.

IT 175280-54-3

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(nucleotide sequence, IL-4 Stat-binding regulatory element; identifying agents that bind interleukin 4 signal transducer and transcription activator for potential therapeutic use)

L3 ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1994:550398 HCAPLUS

DOCUMENT NUMBER: 121:150398

TITLE: Involvement of the transcription factor PU.1/Spi-1 in myeloid cell-restricted expression of an interferon-inducible gene encoding the human high-affinity Fcγ receptor

AUTHOR(S): Perez, Christophe; Coeffier, Eliane; Moreau-Gachelin, Francoise; Wietzerbin, Juana; Benech, Philippe D.

CORPORATE SOURCE: Unite 365 INSERM, Institut Curie, Paris, 75231, Fr.

SOURCE: Molecular and Cellular Biology (1994), 14(8), 5023-31

CODEN: MCEBD4; ISSN: 0270-7306

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Induction by gamma interferon (IFN-γ) of the gene encoding the human high-affinity Fcγ receptor (FcγR1) in myeloid cells requires an IFN-γ response origin (GRR) and a myeloid cell-activating transcription element (MATE). GRR and MATE interact with factors to form, resp., an IFN-γ-activating complex (GIRE-BP), depending on the phosphorylation of the 91-kDa protein (subunit of ISGF3), and a cell-type-specific complex (MATE-BP). Although GIRE-BP is detected in cells of different origins after IFN-γ treatment, the presence of MATE-BP was found to be restricted to B- and myeloid cell lines. Sequence anal. of a cDNA encoding a polypeptide recognizing specifically the MATE motif led to the identification of this product as the proto-oncogene PU.1/Spi-1, a transcriptional activator expressed in myeloid and B cells. Expression of this factor in nonhematopoietic cells allowed IFN-γ-induced expression of a reporter gene under control of the GRR and MATE sequences. The presence of these motifs in other gene promoters indicates that the binding of PU.1/Spi-1 and IFN regulatory proteins to their resp. motifs could be part of a general mechanism leading to cell-type-restricted and IFN-induced gene expression.

IT 157547-19-8, -165--78-DNA (human FcγR IgG fragment Fc receptor gene GRR element and MATE element and promoter region containing fragment)

RL: PRP (Properties)

09/744875

(nucleotide sequence and function of)

E1 THROUGH E15 ASSIGNED

FILE 'REGISTRY' ENTERED AT 15:14:30 ON 05 FEB 2004

L4 15 SEA FILE=REGISTRY ABB=ON PLU=ON (175280-54-3/BI OR
309905-34-8/BI OR 157547-19-8/BI OR 211046-24-1/BI OR
257898-64-9/BI OR 257898-65-0/BI OR 294679-80-4/BI OR
387408-25-5/BI OR 405193-24-0/BI OR 438069-80-8/BI OR
478232-52-9/BI OR 478608-20-7/BI OR 488765-15-7/BI OR
524984-78-9/BI OR 566963-54-0/BI)

L5 15 L4 AND L1

L5 ANSWER 1 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN
RN 566963-54-0 REGISTRY
CN 43: PN: WO03060090 SEQID: 44 claimed DNA (9CI) (CA INDEX NAME)
CI MAN
SQL 100

SEQ 1 gtaccttccc gtaaatecct ccccttcccgaattacacc cgcgtatttc
=====

51 ccagaaaagg aactgtagat ttctaggaat tcaatccttg gccacgcgtc
=====

HITS AT: 44-63

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 139:132464

L5 ANSWER 2 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN
RN 524984-78-9 REGISTRY
CN 17: PN: WO03040313 SEQID: 17 unclaimed DNA (9CI) (CA INDEX NAME)
CI MAN
SQL 100

SEQ 1 gtaccttccc gtaaatecct ccccttcccgaattacaca cgcgtatttc
=====

51 ccagaaaagg aactgtagat ttctaggaat tcaatccttg gccacgcgtc
=====

HITS AT: 44-63

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:380415

L5 ANSWER 3 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN
RN 488765-15-7 REGISTRY
CN DNA, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-A-G-G-A-A-C) (9CI) (CA INDEX
NAME)

OTHER NAMES:

CN 93: PN: US20030017499 SEQID: 93 claimed DNA
CI MAN
SQL 20

SEQ 1 gtatttccca gaaaaggaac
=====

Searcher : Shears 571-272-2528

09/744875

HITS AT: 1-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:119583

L5 ANSWER 4 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN
RN 478608-20-7 REGISTRY
CN DNA, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-A-G-G-A-A-C) (9CI) (CA INDEX
NAME)
OTHER NAMES:
CN 93: PN: W002101351 SEQID: 93 unclaimed DNA
CI MAN
SQL 20

SEQ 1 gtatttccca gaaaaggaac
=====

HITS AT: 1-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:34116

L5 ANSWER 5 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN
RN 478232-52-9 REGISTRY
CN DNA, d(A-G-C-C-T-G-A-T-T-T-C-C-C-C-G-A-A-A-T-G-A-C-G-G-C-A-C-G-C-A-G-
C-C) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 31: PN: W002098916 PAGE: 28 unclaimed sequence
CI MAN
SQL 33

SEQ 1 agcctgattt ccccgaaatg acggcacgca gcc
=====

HITS AT: 2-26

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:34237

L5 ANSWER 6 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN
RN 438069-80-8 REGISTRY
CN DNA, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-A-G-G-A-A-C) (9CI) (CA INDEX
NAME)
OTHER NAMES:
CN 5: PN: US20020077308 SEQID: 5 unclaimed DNA
CI MAN
SQL 20

SEQ 1 gtatttccca gaaaaggaac
=====

HITS AT: 1-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:52346

L5 ANSWER 7 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

Searcher : Shears 571-272-2528

09/744875

RN 405193-24-0 REGISTRY
CN DNA, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-A-G-G-A-A-C) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 67: PN: W00222809 SEQID: 63 unclaimed DNA
CI MAN
SQL 20

SEQ 1 gtattttccca gaaaaggaac
=====

HITS AT: 1-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:261808

L5 ANSWER 8 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN
RN 387408-25-5 REGISTRY
CN 43: PN: W00200721 SEQID: 43 unclaimed DNA (9CI) (CA INDEX NAME)
CI MAN
SQL 100

SEQ 1 gtaccttccc gtaaatecct ccccttcccg gaattacacc cgcgtatttc
=====

51 ccagaaaagg aactgtagat ttctaggaat tcaateccttg gccacgcgtc
=====

HITS AT: 44-63

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:84703

L5 ANSWER 9 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN
RN 309905-34-8 REGISTRY
CN 37: PN: W00068381 SEQID: 37 unclaimed DNA (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 35: PN: W00177171 SEQID: 48 unclaimed DNA
CI MAN
SQL 100

SEQ 1 gtaccttccc gtaaatecct ccccttcccg gaattacacc cgcgtatttc
=====

51 ccagaaaagg aactgtagat ttctaggaat tcaateccttg gccacgcgtc
=====

HITS AT: 44-63

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 135:317481

REFERENCE 2: 133:359539

L5 ANSWER 10 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN
RN 294679-80-4 REGISTRY
CN 60: PN: W00053761 SEQID: 59 unclaimed DNA (9CI) (CA INDEX NAME)
CI MAN
SQL 100

09/744875

SEQ 1 gtaccttccc gtaaatecct ccccttcccg gaattacaca cgcgtatttc
=====

51 ccagaaaagg aactgtagat ttctaggaat tcaatccttg gccacgcgtc
=====

HITS AT: 44-63

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 133:248680

L5 ANSWER 11 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN 257898-65-0 REGISTRY

CN DNA, d(G-C-C-T-G-A-T-T-T-C-C-C-C-G-A-A-A-T-G-A-C-G-G-C-A),
double-stranded complementary (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN DNA, d(T-G-C-C-G-T-C-A-T-T-T-C-G-G-G-G-A-A-A-T-C-A-G-G-C),
double-stranded complementary (9CI)

OTHER NAMES:

CN 4: PN: WO0006696 SEQID: 2 claimed DNA

CI MAN

SQL 25

SEQ 1 gcctgatttc cccgaaatga cggca
=====

HITS AT: 1-25

REFERENCE 1: 132:146659

L5 ANSWER 12 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN 257898-64-9 REGISTRY

CN DNA, d(A-G-A-T-T-T-C-T-A-G-G-A-A-T-T-C-A-A-A-T-C), double-stranded
complementary (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN DNA, d(G-A-T-T-T-G-A-A-T-T-C-C-T-A-G-A-A-A-T-C-T), double-stranded
complementary (9CI)

OTHER NAMES:

CN 3: PN: WO0006696 SEQID: 1 claimed DNA

CI MAN

SQL 21

SEQ 1 agatttctag gaattcaaat c
=====

HITS AT: 1-21

REFERENCE 1: 132:146659

L5 ANSWER 13 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN 211046-24-1 REGISTRY

CN DNA, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-A-G-G-A-A-C) (9CI) (CA INDEX
NAME)

CI MAN

SQL 20

SEQ 1 gtatttccca gaaaaggaac
=====

HITS AT: 1-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Searcher : Shears 571-272-2528

09/744875

REFERENCE 1: 129:166205

L5 ANSWER 14 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN 175280-54-3 REGISTRY

CN DNA, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-A-G-G-A-A-C), double-stranded
complementary (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Deoxyribonucleic acid, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-A-G-G-A-A-C),
double-stranded complementary

CN DNA, d(G-T-T-C-C-T-T-T-T-C-T-G-G-G-A-A-A-T-A-C), double-stranded
complementary (9CI)

OTHER NAMES:

CN 5: PN: WO0006696 SEQID: 3 claimed DNA

CI MAN

SQL 20

SEQ 1 gtattttccca gaaaaggaac

=====

HITS AT: 1-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 132:146659

REFERENCE 2: 126:166477

REFERENCE 3: 124:281083

L5 ANSWER 15 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN 157547-19-8 REGISTRY

CN DNA (human immunoglobulin G receptor gene promoter region GRR
element plus MATE element-containing fragment) (9CI) (CA INDEX
NAME)

OTHER CA INDEX NAMES:

CN Deoxyribonucleic acid (human immunoglobulin G receptor gene promoter
region GRR element plus MATE element-containing fragment)

OTHER NAMES:

CN DNA (human FcγR IgG fragment Fc receptor gene GRR element and
MATE element and -165--78 promoter region containing fragment)

CI MAN

SQL 88

SEQ 1 gtttcaagga ttgagatgt atttcccaga aaaggaacat gatgaaaatg

== =====

51 gtcagaaaag gcaatttcct tcctcttttc taatttgg

HITS AT: 19-38

REFERENCE 1: 121:150398

FILE 'HOME' ENTERED AT 15:15:00 ON 05 FEB 2004